These multifaceted metabolic effects position dual GLP-1/GIP receptor agonists as superior therapeutic candidates for MASLD, especially in patients with coexisting obesity and T2DM, where dysregulated glucose and lipid metabolism drive the progression of the disease
doi:10.3390/ijerph17051794 Lpez-Botella A, Velasco I, Acin M, et al
For General Wellness and Detox : 1 injection every 1-2 weeks, depending on your exposure to toxins and stress levels
Eligible participants had CKD defined as either an eGFR of 5075 mL/min/1.73 m 2 with UACR 3005,000 mg/g, or an eGFR of 25 to 50% eGFR decline, ESKD, or all-cause mortality [81]
The most commonly reported relate to digestive discomfort, such as nausea or looser stools, and sometimes a more pronounced body odour
/ If recommended, keep a log of your blood sugar levels and blood pressure readings during the first month of treatment